Informing Congress: A Return of the OTA?

In the midst of this summer's rancorous US House of Representatives debate over the legality of cloning, an exasperated Rep. Louise Slaughter (D-N.Y.) complained, "Mr. Speaker, we really should not be debating this at all. None of us is equipped to do so. We simply do not know enough." Rep. Peter Deutsch (D-Fla.) agreed. "In my nine years in this chamber, this is the least informed collectively that the 435 members of this body have ever been on any issue." In the end, the July 31, 265-162 vote

Written byTed Agres
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Rep. Rush Holt (D-N.J.), one of two physicists in Congress, believes the cloning experience highlights the need for better scientific and technical information on Capitol Hill. He has introduced legislation (HR 2148) to bring back the Office of Technology Assessment (OTA), a congressional entity that had provided legislators with information and reports on a variety of scientific and technical topics for more than 20 years. Until it was disbanded in 1995, a victim of politics and budget cuts, OTA employed some 200 staffers and published up to 55 reports per year, some book-length, and had another 30 to 60 projects in progress. OTA's work "ran the gamut of subject matter, with approaches tailored for each topic and congressional request," wrote Rep. Amo Houghton (R-N.Y.), "in memoriam" in 1995. "The agency took on controversial subjects, examining them objectively and comprehensively. It helped us to better understand complex technical issues." Courtesy of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies